Preliminary Final Report
Filed with ASX · · 58 pages · English
Summary by 6ix AI
The report indicates a significant loss for the year, with no dividends declared during the current or previous financial periods. The company also reported on its capital raising activities and the progress of its clinical trials, highlighting encouraging interim results.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Syntara
- Guidance from FDA on amsulostat clinical progression
- Reinstatement to Quotation
- Suspension from Quotation
- Quarterly Appendix 4C Cash Flow Report
- Quarterly Shareholder Report
Later from Syntara
- Positive top-line Phase 2a data confirms competitive profile
- Quarterly Shareholder Report and Appendix 4C
- Skin scarring program to progress on positive Phase1a result
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Amsulostat and Garvan in MRFF funded pancreatic trial
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara